

Anti-EAPII (TTRAP/TDP2)




Caprico
Biotechnologies

Where quality meets standard


- ✓ *High quality*
- ✓ *Reliable*
- ✓ *Meets the standard*

Caprico produces high quality anti-human EAPII/TTRAP/TDP2 antibody

EAPII (also called TTRAP, TDP2) originally was identified as an interacting partner of oncogene ETS1, a founding member of ets transcription factor, and the cytoplasmic domain of CD40, a member of the tumor necrosis factor (TNF) receptor family. EAPII significantly represses ETS1 transcriptional activity and the synergistic transactivation by ETS1 and AP-1 or by ETS1 and NFκB. EAPII/TTRAP also inhibits the transcriptional activation of NFκB induced by CD40 or phorbol 12-myristate 13-acetate (PMA). Recently this protein was also proven to be the first 5'- tyrosyl-DNA phosphodiesterase. EAPII has been demonstrated to have promiscuous protein associations, broad responsiveness to various extracellular signals, and pleiotropic functions in the development of human diseases including cancer and neurodegenerative disease. Emerging data suggest that EAPII is a multi-functional protein: it repairs enzyme (topoisomerase)-mediated DNA damage by removing phosphotyrosine from DNA adducts; involves in multiple signal transduction pathways such as TNF-TNFR, TGFβ and MAPK, and responsive to immune defense including inflammatory response, viral infection and DNA toxins (chemo or radiation therapy). EAPII predominantly localizes to the nucleus, but based on pathological conditions it also localizes in both cytoplasm and nucleus.



A: 42C anti-EAPII monoclonal antibody was used in Western blot. EAPII protein levels in breast carcinoma (MCF7 and MDA-MB-231), prostate carcinoma (PC3 and DU145), liver adenocarcinoma (SK-HEP-1), ovarian adenocarcinoma (SKOV-3), and colon adenocarcinoma (DLD1).



B: Monoclonal anti-EAPII antibody 42C was used for immunohistochemical (IHC) studies of EAPII expression in Head and Neck Squamous Cell Carcinoma (HNSCC). Increased expression of EAPII in (HNSCC). HNSCC tissues stained with control IgG or 42C. Photos (a) and (b) are 200x magnification.

42C


IgG

Anti-EAPII (TTRAP/TDP2)




Caprico
Biotechnologies

Where quality meets standard



Anti EAPII 42C were used in immunohistochemistry (IHC) study: Representative images of a tissue microarray stained with anti-EAPII monoclonal antibody 42C. No EAPII staining is observed in normal bronchial epithelium (a). EAPII is expressed in hyperplastic epithelium (b and c), dysplastic epithelium (d), and lung carcinomas (e and f), demonstrating that Increased expression of EAPII in lung carcinomas.



siRNA transfected HeLa cells were cultured in a slide chamber and fixed at 48 hours. EAPII (Green) and actin (Red) were detected using a polyclonal antibody (220) and Rhodamine-Phalloidin, respectively. The cells were visualized using a confocal microscope.

Catalog Number	Name	Immunogen	Host	Target	Application	Size
100101	Anti-EAPII (42C)	Full-length recombinant EAPII	Mouse	Hu	IHC, Western, IP, ICC, ChIP	100 µg
100103						500 µg
103901	Anti-EAPII (24D)	Full-length recombinant EAPII	Mouse	Hu	IHC, Western, IP, ICC, ChIP	100 µg
103903						500 µg
104001	Anti-EAPII (22B)	Full-length recombinant EAPII	Mouse	Hu	IHC, Western, IP, ICC, ChIP	100 µg
104003						500 µg
204101	Anti-EAPII (220)	Full-length recombinant EAPII	Rabbit	Hu	IHC, Western, IP, ICC	100 µg
204103						500 µg

Caprico Biotechnologies also provides a monoclonal antibody against Ets1, an EAPII /TTRAP /TDP2 related protein. Ets1 plays important role in the immune regulation of B cells, T cells, NK cells, and NK T cells and non-lymphoid organs in adult humans.

References:

- Li et al 2011, *Cell Cycle* 10:19, 3274-3283
- Li et al 2011, *Oncogene* 30:3820-3812
- Ramirez K., et al. (2012). *Immunity* 36 921-932
- Glimcher et al 2004. *Nat. Rev. Immunol.* 4:900-911

Email: info@capricobio.com

Tel: +1 678 691 2143.

<https://www.capricobio.com>